Tag: Sirtex

DOORwaY

DOORwaY-90 study for SIR-Spheres therapy as first-line treatment for hepatocellular carcinoma...

The first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres Y-90...
DOORwaY

First patient enrolled in pivotal LAVA study

The first patient has been enrolled in the LAVA study to evaluate the safety and effectiveness of the BlackSwan Lava liquid embolic system (LES)...
DOORwaY

DOORwaY90 study launches: The first prospective, multicentre US-based trial for registration...

The US Food and Drug Administration (FDA) have approved the DOORwaY90 study, a trial evaluating the safety and efficacy of selective internal radiation therapy...
DOORwaY

Sirtex Medical announces strategic investment in BlackSwan Vascular

Sirtex Medical (Sirtex) has announced a strategic investment in BlackSwan Vascular (BlackSwan), a private company developing therapies in endovascular embolization. The investment provides resources...
DOORwaY

SIR-Spheres Y-90 resin microspheres meet drug registration requirements in China

Sirtex Medical and its shareholders, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) have been issued a “Notice of Drug Clinical Trial Approval” by...

The largest European cohort on the treatment of liver cancer with...

The largest European-wide observational study on the treatment of primary and metastatic liver tumours with SIR-Spheres microspheres (Sirtex) will present its data on safety...
DOORwaY

Sirtex Medical completes enrollment of landmark US RESiN registry

Sirtex Medical reports that enrollment in the US RESiN registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for...
Interventional News for specialists

Sirtex Medical partners with Magle Chemoswed to develop imaging agent

Sirtex Medical has announced a collaboration with Magle Chemoswed, a Sweden-based contract development and manufacturing organisation. The development and commercial agreement grants Sirtex global use...
SIROS

Sirtex Medical launches SIROS system for SIR-Spheres resin microspheres delivery

A new system designed to deliver Yttrium-90 (Y-90) resin microspheres during targeted liver cancer therapies, SIROS (Sirtex) has launched commercially. A company press release states:...
DOORwaY

Sirtex Medical announces collaboration with MIM Software

Sirtex Medical has announced a collaboration with MIM Software. Under the terms of the agreement, Sirtex’s sales teams in the USA, Europe, and other...
NHS

SIRT approved for routine commissioning on the NHS

National Health Service (NHS) England have announced that selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) microspheres will now be routinely commissioned for NHS...

Lessons from randomised controlled trials utilising SIRT in liver cancer

A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...
china

Sirtex prefers US$1.4 billion CDH-CGP bid to Varian’s acquisition offer

Sirtex has announced entering into a binding scheme implementation deed with CDH Genetech (CDH) and China Grand Pharmaceuticals and Healthcare Holdings Limited (CGP). It...

Establishing the evidence base for SIRT in Interventional Oncology

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

SIRT fails to extend survival in the SORAMIC study palliative cohort

  The SORAMIC study, presented at The International Liver Congress, shows that the addition of selective internal radiation therapy (SIRT) to sorafenib in patients with...

Varian signs agreement to acquire Sirtex

Varian Medical has announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical for A$28 per share in cash....

REsect study shows SIRT makes metastatic colorectal cancer patients more likely...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

SIRT significantly better tolerated than sorafenib, but does not increase overall...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...